✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Janoshik
Batch SLU-CA-26A-01
PPARδ Agonist Research Compound
SLU-PP-332 Capsules are a solid-dose research format used in laboratory studies to investigate compounds involved in metabolic and mitochondrial signaling pathways. Research often examines their influence on energy utilization processes, cellular regulation mechanisms, and systemic metabolic responses in controlled experimental models.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
SLU-PP-332 is a small-molecule research compound studied as a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. It is developed for controlled laboratory investigation involving nuclear receptor signaling systems.
In scientific literature, SLU-PP-332 is examined in experimental models evaluating PPARδ-associated transcriptional pathways, metabolic regulatory frameworks, and receptor-mediated gene expression systems under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
SLU-PP-332 is evaluated in research focused on PPARδ receptor activation and nuclear receptor–mediated transcriptional regulation. Experimental studies examine receptor-binding dynamics and downstream gene expression signaling systems within controlled laboratory environments.
Research frameworks explore its interaction with metabolic regulatory pathways and transcriptional signaling models under structured experimental conditions.
Research into peroxisome proliferator-activated receptors (PPARs) led to the development of selective receptor agonists for experimental evaluation. Compounds targeting PPARδ have been studied for their role in transcriptional regulation and metabolic signaling systems.
SLU-PP-332 emerged within this research context as a selective agonist evaluated in controlled laboratory models examining nuclear receptor pathway interaction.
Laboratory investigations into SLU-PP-332 have focused on PPARδ activation models and nuclear receptor–mediated gene expression systems. Research frameworks evaluate receptor-binding interaction, transcriptional pathway regulation, and metabolic signaling mechanisms under controlled in vitro and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of SLU-PP-332. Independent third-party testing verifies purity, identity, and batch specifications prior to release.
The product is supplied in capsule form for laboratory research purposes. No additional materials are included.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Design, synthesis, and evaluation of simple phenol amides as ERRγ agonists.
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$180.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$10.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$70.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$95.00
